跳至主要内容
临床试验/CTRI/2024/10/074809
CTRI/2024/10/074809招募中不适用

Evaluation of clinical outcome in Asian patients with localized rectal adenocarcinoma managed with watch-and-wait approach by developing a multinational collaborative database.

Tata Memorial Hospital1 个研究点 分布在 1 个国家目标入组 337 人开始时间: 2024年10月15日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
337
试验地点
1
主要终点
To determine the local regrowth rates at 2 years in Asian patients managed with the watch-and-wait strategy after neoadjuvant therapy in rectal cancer.

研究概览

简要总结

The standard treatment approach of localized rectal adenocarcinoma involves neoadjuvant radiotherapy and chemotherapy followed by assessment for surgery and optional adjuvant chemotherapy. However, such patients who achieve complete of near complete clinical response after neoadjuvant therapy are increasingly being managed with the ‘Watch-and-Wait strategy’ in the recent years. Although safety of such policy has been established, the patient population in the published studies are not represented well by Asian population. Moreover, the data about safety of such policy in the setting of modern neoadjuvant strategies is limited. We propose a multinational collaborative prospective database study in Asia to systematically collect data on patients being managed with such a strategy. The target population is patients with localized rectal adenocarcinoma achieving near complete or complete response being managed by the Watch-and-Wait strategy. The primary end point being local regrowth and other survival and quality of life end points will be evaluated as well. A secure multinational database will be generated over 5 years with an estimated expected minimal sample size of 337 patients over 5 years across 7-10 Asian institutes to precisely evaluate the required endpoints. Ethical and legal requirements will be met at each participating institute.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • 1.Histologically confirmed diagnosis of adenocarcinoma of the rectum 2.Clinical stage T1-T4, N0-N2, M0 at diagnosis 3.ECOG Performance status 0-1 4.Neoadjuvant treatment with either short course or long course radiation therapy and / or chemotherapy 5.Complete or near complete clinical response after neoadjuvant therapy 6.Patients willing to be on watch-and-wait strategy.
  • 7.The distance from anal verge of tumour up to 10 cm (Mid and low rectal tumours).

排除标准

  • 1.Recurrent rectal cancer 2.Patients with any other concurrent medical or psychiatric condition or disease which would make them inappropriate candidates for entry into this study.
  • 3.Not willing to consent for the study or to follow up routinely 4.Patients who cannot read or understand the language of QoL.

结局指标

主要结局

To determine the local regrowth rates at 2 years in Asian patients managed with the watch-and-wait strategy after neoadjuvant therapy in rectal cancer.

时间窗: 2 years

次要结局

  • To determine the rates of overall survival (OS) at 2 years and 5 years(2 years)
  • To determine disease free survival (DFS) at 2 years and 5 years(2 years)
  • To determine the rates of colostomy free survival at 2 years and 5 years(2 years)
  • To determine the clinical complete response rates (cCR) and regrowth rates with respect to various neoadjuvant treatment approaches(2 years)
  • To determine Quality of life (QOL) of patients managed with Watch-and-wait policy.(2 years)
  • To determine compliance of these patients to recommended surveillance protocol.(5 years)

研究者

申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Shivakumar Gudi

Tata Memorial Hospital

研究点 (1)

Loading locations...

相似试验